Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts

In nonobese diabetic (NOD) mice with overt new-onset type 1 diabetes mellitus (T1DM), short-term treatment with a “triple-therapy” regimen [rapamycin plus agonist IL-2-related and antagonist-type, mutant IL-15-related Ig fusion proteins (IL-2.Ig and mutIL-15.Ig)] halts autoimmune destruction of insulin-producing beta cells and restores both euglycemia and immune tolerance to beta cells. Increases in the mass of insulin-producing beta cells or circulating insulin levels were not linked to the restoration of euglycemia. Instead, the restoration of euglycemia was linked to relief from an inflammatory state that impaired the host's response to insulin. Both restoration of immune tolerance to beta cells and relief from the adverse metabolic effects of an inflammatory state in insulin-sensitive tissues appear essential for permanent restoration of normoglycemia in this T1DM model. Thus, this triple-therapy regimen, possessing both tolerance-inducing and select antiinflammatory properties, may represent a prototype for therapies able to restore euglycemia and self-tolerance in T1DM.

[1]  R. Steinman,et al.  Dendritic cell–expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice , 2007, The Journal of experimental medicine.

[2]  G. Hotamisligil,et al.  Inflammation and metabolic disorders , 2006, Nature.

[3]  J. Flier,et al.  Attenuation of leptin and insulin signaling by SOCS proteins , 2006, Trends in Endocrinology & Metabolism.

[4]  Yves Konigshofer,et al.  Nonobese diabetic mice express aspects of both type 1 and type 2 diabetes , 2006, Proceedings of the National Academy of Sciences.

[5]  A. Goldfine,et al.  Inflammation and insulin resistance. , 2006, The Journal of clinical investigation.

[6]  J. Bluestone,et al.  Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. , 2006, The Journal of clinical investigation.

[7]  J. Flier,et al.  Overexpression of suppressor of cytokine signaling 3 in adipose tissue causes local but not systemic insulin resistance. , 2006, Diabetes.

[8]  A. Rudensky,et al.  A function for interleukin 2 in Foxp3-expressing regulatory T cells , 2005, Nature Immunology.

[9]  Saroja Ramanujan,et al.  A comprehensive review of interventions in the NOD mouse and implications for translation. , 2005, Immunity.

[10]  Michel Goldman,et al.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. , 2005, The New England journal of medicine.

[11]  S. Bonner-Weir,et al.  Five stages of evolving beta-cell dysfunction during progression to diabetes. , 2004, Diabetes.

[12]  T. Strom,et al.  Targeting IL-15 Receptor-Bearing Cells with an Antagonist Mutant IL-15/Fc Protein Prevents Disease Development and Progression in Murine Collagen-Induced Arthritis1 , 2004, The Journal of Immunology.

[13]  J. Habener,et al.  Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. , 2004, Diabetes.

[14]  V. Kuchroo,et al.  Tim-3 inhibits T helper type 1–mediated auto- and alloimmune responses and promotes immunological tolerance , 2003, Nature Immunology.

[15]  T. Strom,et al.  Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. , 2003, Immunity.

[16]  J. Bluestone,et al.  TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes , 2003, Nature Medicine.

[17]  V. Sharma,et al.  CD103 mRNA levels in urinary cells predict acute rejection of renal allografts1 , 2003, Transplantation.

[18]  T. Strom,et al.  Cytokines in the treatment and prevention of autoimmune responses-a role of IL-15. , 2003, Advances in experimental medicine and biology.

[19]  D. Harlan,et al.  Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. , 2002, The New England journal of medicine.

[20]  T. Strom,et al.  Tracking the Immunoregulatory Mechanisms Active During Allograft Tolerance1 , 2002, The Journal of Immunology.

[21]  T. Mandrup-Poulsen,et al.  A choice of death – the signal-transduction of immune-mediated beta-cell apoptosis , 2001, Diabetologia.

[22]  T. Strom,et al.  An Antagonist IL-15/Fc Protein Prevents Costimulation Blockade-Resistant Rejection1 , 2001, The Journal of Immunology.

[23]  T. Waldmann,et al.  Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. , 2001, Immunity.

[24]  T. Strom,et al.  IL-15 and IL-2: a matter of life and death for T cells in vivo , 2001, Nature Medicine.

[25]  S. Bonner-Weir,et al.  Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.

[26]  T. Strom,et al.  Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance , 1999, Nature Medicine.

[27]  P. Nickerson,et al.  IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice. , 1999, Journal of immunology.

[28]  K. Polonsky,et al.  Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. , 1999, Diabetes.

[29]  Y. S. Kim,et al.  Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fc gamma2a protein blocks delayed-type hypersensitivity. , 1998, Journal of immunology.

[30]  C. Kahn,et al.  Development of a Novel Polygenic Model of NIDDM in Mice Heterozygous for IR and IRS-1 Null Alleles , 1997, Cell.

[31]  Dennis R. Helsel,et al.  Less than obvious - statistical treatment of data below the detection limit , 1990 .

[32]  S. Sandler,et al.  Inhibitory effects of interleukin 1 on insulin secretion, insulin biosynthesis, and oxidative metabolism of isolated rat pancreatic islets. , 1987, Endocrinology.

[33]  A. Monaco,et al.  An improved method for isolation of mouse pancreatic islets. , 1985, Transplantation.

[34]  J. Mordes,et al.  Immunology of insulin-dependent diabetes mellitus. , 1985, Annual review of immunology.